Recent business development and
financial performance of
Bio-Techne Corp (NASDAQ: TECH) have stirred key market interests.
M&T Bank Corp and
Atria Wealth Solutions Inc invested $1.02 million and $250,000, respectively while
First Horizon Advisors Inc accumulated a stake of $40000.
Thermo Fisher Scientific recently entered a distribution partnership with Bio-Techne.
Nikon Instruments Inc too, entered a strategic partnership to expand market access. Bio-Techne has received
European IVDR certification for its chronic disease diagnostic test and surpasses 10,000 peer-reviewed publications citing
RNAscope technology.
Bio-Techne shares crossed Above 200 DMA, indicating a bullish trend.
Operating performance has missed analyst expectations by 36%, however, Q3 2024 earnings beat expectations. Subsequent to
Mixed Q2 Fiscal 2024 results, the corporation anticipates higher intrinsic values for Bio-Techne shares. They've also achieved
ISO 13485 certification for manufacturing facilities in Wallingford, CT, unveiling Neil ten Kortenaar as its new CEO. A strategic partnership was embarked with
Lunaphore and
Cell Signaling Technology. Ahead of the AACR 2024, they were prepped to present at Barclays Global Healthcare Conference. Bio-Techne's acquisition of
Lunaphore further expanded its spatial biology offerings.
Bio-Techne Corp TECH News Analytics from Thu, 01 Oct 2020 07:00:00 GMT to Sun, 12 May 2024 09:51:22 GMT -
Rating 5
- Innovation 7
- Information 9
- Rumor 1
